Canada’s Drug Agency | Drugs, Health Technologies and Systems.

dupilumab

Details

Files
Generic Name:
dupilumab
Project Status:
Active
Therapeutic Area:
Prurigo nodularis (PN)
Manufacturer:
sanofi-aventis Canada Inc.
Call for patient/clinician input open:
Brand Name:
Dupixent
Project Line:
Reimbursement Review
Project Number:
SR0876-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the treatment of adult patients with moderate-to-severe PN whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Dupixent can be used with or without topical corticosteroids.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
​Dupixent is indicated for the treatment of adult patients with moderate-to-severe prurigo nodularis (PN) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Dupixent can be used with or without topical corticosteroids.
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Key Milestones2
Call for patient/clinician input open12-Nov-24
Call for patient/clinician input closed10-Jan-25
Submission received20-Dec-24
Submission accepted13-Jan-25
Review initiated14-Jan-25
Draft CADTH review report(s) provided to sponsor for comment09-Apr-25
Deadline for sponsors comments22-Apr-25
CADTH review report(s) and responses to comments provided to sponsor15-May-25
Expert committee meeting (initial)28-May-25
Draft recommendation issued to sponsorJune 09, 2025
To
June 11, 2025
Draft recommendation posted for stakeholder feedback19-Jun-25
End of feedback period04-Jul-25

Files

Patient and Clinician Group Input View PDF
Last Updated : March 27, 2025